Comparative Pharmacology
Head-to-head clinical analysis: MEZOFY versus PROMETHAZINE W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZOFY versus PROMETHAZINE W CODEINE.
MEZOFY vs PROMETHAZINE W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEZOFY is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits nociceptive transmission; promethazine is a phenothiazine derivative with H1-receptor antagonism, anticholinergic, and antiemetic effects.
MEZOFY (mexiletine) 200 mg orally every 8 hours; may increase to 300 mg every 8 hours if needed.
10 mL (1 mg codeine, 6.25 mg promethazine per 5 mL) orally every 4-6 hours as needed for cough. Maximum: 60 mL per day. Do not exceed 5 days.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h in CrCl <30 mL/min)
Promethazine: 10-19 hours (terminal). Codeine: 2.5-3.5 hours (terminal); prolonged in renal impairment.
Renal: 60% unchanged; biliary/fecal: 25% as metabolites; 15% other
Promethazine: renal (70% as metabolites, <1% unchanged), fecal (20-30%). Codeine: renal (90%, of which 5-10% unchanged, rest as metabolites), fecal (minor).
Category C
Category A/B
Antiemetic/Antivertigo
Antihistamine / Antiemetic